Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.95 CAD 1.04% Market Closed
Market Cap: 126.1m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Arch Biopartners Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arch Biopartners Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Arch Biopartners Inc
XTSX:ARCH
Total Liabilities & Equity
CA$1.5m
CAGR 3-Years
-17%
CAGR 5-Years
10%
CAGR 10-Years
23%
Abcellera Biologics Inc
NASDAQ:ABCL
Total Liabilities & Equity
$1.5B
CAGR 3-Years
14%
CAGR 5-Years
133%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Total Liabilities & Equity
CA$331.5k
CAGR 3-Years
-5%
CAGR 5-Years
23%
CAGR 10-Years
-20%
Innovotech Inc
XTSX:IOT
Total Liabilities & Equity
CA$1.1m
CAGR 3-Years
1%
CAGR 5-Years
36%
CAGR 10-Years
12%
No Stocks Found

Arch Biopartners Inc
Glance View

Market Cap
125.3m CAD
Industry
Life Sciences Tools & Services

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
0.29 CAD
Overvaluation 85%
Intrinsic Value
Price

See Also

What is Arch Biopartners Inc's Total Liabilities & Equity?
Total Liabilities & Equity
1.5m CAD

Based on the financial report for Jun 30, 2024, Arch Biopartners Inc's Total Liabilities & Equity amounts to 1.5m CAD.

What is Arch Biopartners Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
23%

Over the last year, the Total Liabilities & Equity growth was 9%. The average annual Total Liabilities & Equity growth rates for Arch Biopartners Inc have been -17% over the past three years , 10% over the past five years , and 23% over the past ten years .

Back to Top